newsfilter
← Latest News
GlobeNewswire·

Outlook Therapeutics to Present at the Virtual Investor 2022 Top Picks Conference

ISELIN, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today an